Skip to main
ZYME
ZYME logo

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks Inc exhibits a promising financial outlook due to its robust clinical development pipeline, highlighted by the significant improvements in progression-free survival (PFS) and overall survival (OS) demonstrated by its lead clinical candidate, Ziihera, in combination with chemotherapy. The company's unique position as a royalty-driven organization is further strengthened by anticipated high-margin revenue streams, including tiered royalties from JAZZ's peak sales estimates for Ziihera and additional mid-single-digit royalties from Johnson & Johnson. Furthermore, Zymeworks maintains a solid financial foundation with $299 million in cash and $440 million associated with near-term milestones, providing a strong base for future growth and development.

Bears say

Zymeworks Inc faces significant risks that contribute to a negative outlook on its stock, particularly due to potential failures in clinical trials related to efficacy and safety for its lead candidate, zanidatamab, as well as challenges in securing manufacturing scalability. Additionally, the company's reliance on external financing in a capital-intensive biotechnology environment raises concerns about insolvency if market conditions deteriorate or if it fails to raise sufficient funds, which could also lead to substantial dilution for current shareholders. Moreover, recent adjustments to revenue forecasts stemming from the discontinuation of certain pipeline assets further exacerbate concerns regarding the company's future financial performance and market competitiveness.

Zymeworks Inc (ZYME) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 8 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.